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Clinical trials are typically conducted over a population within a deﬁned time period in order to illumi-
nate certain characteristics of a health issue or disease process. These cross-sectional studies give us a
‘snapshot’ of this disease process over a large number of people but do not allow us to model the tem-
poral nature of disease, thereby allowing for modelling detailed prognostic predictions. The aim of this
paper is to explore an extension of the temporal bootstrap to identify intermediate stages in a disease
process and sub-categories of the disease exhibiting subtly different symptoms. Our approach is com-
pared to a strawman method and investigated in its ability to explain the dynamics of progression on bio-
medical data from three diseases: Glaucoma, Breast Cancer and Parkinson’s disease. We focus on creating
reliable time-series models from large amounts of historical cross-sectional data using the temporal
bootstrap technique. Two issues are explored: how to build time-series models from cross-sectional data,
and how to automatically identify different disease states along these trajectories, as well as the transi-
tions between them. Our approach of relabeling trajectories allows us to explore the temporal nature of
how diseases progress even when time-series data is not available (if the cross-sectional study is large
enough). We intend to expand this research to deal with multiple studies where we can combine both
cross-sectional and longitudinal datasets and to focus on the junctions of the trajectories as key stages
in the progression of disease.
 2012 Elsevier Inc. All rights reserved.1. Introduction
Clinical trials are typically conducted over a population within a
deﬁned time period in order to illuminate certain characteristics of
a health issue or disease process. These cross-sectional studies give
us a ‘snapshot’ of such disease processes over a large number of
people but do not allow us to model the temporal nature of dis-
ease. Longitudinal studies on the other hand, are used to explore
how these processes develop over time in a number of people
but can be expensive and time-consuming, and many studies only
cover a relatively small window within the disease process. We are
interested in creating reliable time-series models from large
amounts of historical cross-sectional data using a novel technique,
the temporal bootstrap that we previously developed [1,2]. In this
paper we explore an extension of the temporal bootstrap, which al-
lows us to identify intermediate stages in a disease process and
sub-categories of known diseases with subtly different symptoms.
This newmethod is compared to a strawman method and explored
in its ability to inform us about the dynamics of the disease. Thell rights reserved.
l University, Kingston Lane,
251686.
ephen.swift@brunel.ac.uk (S.method is investigated in its ability to explain the dynamics of pro-
gression on biomedical data from three diseases: Glaucoma, Breast
Cancer and Parkinson’s disease. These diseases are very different
but are characterised by a similarity in how their data have been
collected as a cross-sectional study over a relatively large
population.
There is already a large amount of work that explores the min-
ing of cross-sectional biomedical data to make predictions or
understand the relationships between variables [3–5]. Whilst some
studies involve learning computational and statistical time-series
models of progression from longitudinal data such as [6–8], many
datasets are cross-sectional and the time dimension is not mea-
sured due to the expensive nature of these studies across an entire
population, despite the inherently temporal nature of disease. Our
methods to build pseudo time-series (PTS) from cross sectional
data use a combination of distance metrics, graph theoretical oper-
ations and bootstrapping [2,9,10]. This approach results in trajecto-
ries through the data space starting at healthy data regions and
ending at cases of advanced disease. In this paper, we exploit a no-
vel approach that uses Hidden Markov Models with increasing
numbers of hidden states to identify interesting states of the dis-
ease process (whether they are multiple end states representing
different variations on the same disease, or key stages in the pro-
gression of a disease) and test it on three real clinical datasets.
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regions of interest at key junctions and the ‘extreme’ end of the tra-
jectories in a number of different medical datasets: namely a glau-
coma study (glaucoma is a leading cause of irreversible blindness
in the world) based upon two different medical tests, a breast can-
cer (BC) study based upon tumour examinations (the incidence of
breast cancer is rising among women in many European countries,
affecting up to 1 in 16 women [11]), and a Parkinson’s disease (PD)
study based upon speech pattern data (due to the ageing of popu-
lations, Parkinson’s disease has become an increasing public health
issue [12]). All datasets are cross-sectional.
The analysis in this paper involves using a combination of the
temporal bootstrap [10,13] and retraining a Hidden Markov Model
(HMM) by unlabelling the healthy/disease states in order to cluster
the data into increasingly ﬁne-grain regions using the Expectation
Maximisation (EM) algorithm [14]. In the next section we formally
describe the pseudo time-series and describe the process in more
detail. We also describe the datasets that are used for exploring
the trajectories, including both real biomedical and simulated data.
Finally we explore the comparison of the trajectories within the
medical context before concluding.2. Methods
2.1. The discovery of disease state transitions
Building pseudo time-series involves plotting trajectories
through cross-sectional data based upon distances between each
point using prior knowledge of healthy and disease states. These
trajectories can then be used to build temporal models such as dy-
namic Bayesian networks [15–18] and Hidden Markov Models to
make forecasts [9,19,20].
The temporal bootstrap involves resampling data from a cross-
sectional study and repeatedly building trajectories through the
samples in order to build more robust time-series models. Each
trajectory begins at a randomly selected datum from a healthy
individual and ends at a random datum classiﬁed as diseased.
The trajectory is determined by the shortest path of Euclidean dis-
tances between these two points. The data is ﬁrst standardised to a
mean l of zero and a standard deviation r of one as we found that
this led to better HMM models. We use the Floyd–Warshall algo-
rithm [21], a well established algorithm used to ﬁnd the shortest
path in a weighted graph.
Let a dataset D be deﬁned as a real valued matrix where m
(rows) is the number of samples – here patients – and n (columns)
is the number of variables – clinical test data. We deﬁne D(i) as the
ith row of matrix D. The vector C = [c1,c2, ...,cm] represents deﬁned
classes, where each ci 2 {0,1} corresponds to the sample i, ci = 0
represents that sample i is a healthy case, and ci = 1 represents that
sample i is a diseased case. These classiﬁcations are based upon the
diagnoses made by experts. We deﬁne a time-series as a real val-
ued T (row) by n (column) matrix where each row corresponds
to an observation measured over T time points. We say that if
T(i) was observed before T(j) then i < j.
We deﬁne a set of pseudo time-series indices as P = {p1,p2, ...,pk}
where each pi is a T length vector where T > 0. We deﬁne pij as the
jth element of pi and each pij 2 {1, ...,m}. We deﬁne the function
F(pi) = [pi1, ...,piT] as creating a T by n matrix where each row of
F(pi) = D(pij). A pseudo time-series can be constructed from each
pi using this operator. For example, if a pseudo time-series index
vector p1 = [3,7,2] then F(p1) is a matrix where the ﬁrst row is
D(3), the second row is D(7) and the third row is D(2). The corre-
sponding class vector of each pseudo time-series generated by
F(pi) is given by G(pi) = [C(pi1), ...,C(PiT)].
To demonstrate this notation consider the following example:Let the data matrix D be deﬁned as:
D ¼
d11 d12 d13
d21 d22 d23
d31 d32 d33
d41 d42 d43
2
6664
3
7775; dij 2 R
Let the corresponding class vector be C = [c1,c2,c3,c4]. If
P = {p1,p2} where p1 = [1,3,1] and p2 = [2,3,1] then:
Fðp1Þ ¼
d11 d12 d13
d31 d32 d33
d11 d12 d13
2
64
3
75; Gðp1Þ ¼ ½c1; c3; c1
and
Fðp2Þ ¼
d21 d22 d23
d31 d32 d33
d11 d12 d13
2
64
3
75; Gðp2Þ ¼ ½c2; c3; c1
To summarise we have deﬁned a set of k pseudo time-series
with their associated class labels, sampled from the cross sectional
data D indexed by the elements of pi.
The elements of pi are determined based upon a uniform ran-
dom sampling procedure with replacement. The ordering of the
elements in pi is based upon randomly selecting a start and end
in the pi such that the associated classiﬁcations are cstart = 0 and
cend = 1. This means that the time-series will progress from a
healthy state to a disease state. The ordering is then determined
by the shortest path, calculated based upon the Floyd Warshall
algorithm applied to the Euclidean distance matrix between sam-
ples in F(pi). See Algorithm 1 below for the full details:
Algorithm 1
Input: Cross section data D; class labels C, sample size T;
number of pseudo time-series k
1. Standardise dataset D to l = 0 and r = 1
2. for i = 1 to k
3. Uniformly randomly sample (with replacement) T row
indices from D to create di such that there is at least one
healthy and one diseased class (in C) corresponding to any
of the indices in di
4. Uniformly randomly select a row index from di, start, from
where 1 6 start 6 T and an endpoint, end, where
1 6 end 6 Twhere C(di, start) represents a healthy class and
C(di, end) represents a diseased class
5. Construct a T  T matrix, Wi, of Euclidean distances
between each D(dia) and D(dib) for all combinations of
indices in di
6. Order di to create d

i based upon the shortest path
between D(di, start) and D(di, end) given the weighted graph
Wi using the Floyd–Warshall algorithm [21] constrained
so that every index in di is included in the path
7. Add the ordered di to the set of pseudo time-series P
8. end for
9. Use the set P of k pseudo time-series to train the pseudo
time-series model
Output: Pseudo Time-Series Model
A key novelty of the work in this paper is the use of the tempo-
ral bootstrap in conjunction with Algorithm 2, below, to generate
and explore the transitions of the different states within the trajec-
tories that are discovered from the selected data. Essentially, it
starts by searching for h = 3 hidden states (one more than the ori-
ginal ‘healthy’ and ‘disease’), whilst learning a HMM. We have
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ability to learn hidden underlying states in a temporal process. The
HMM we use involves one hidden variable that is conditioned on
the hidden variable at the previous time point and n observed vari-
ables that are conditioned upon the hidden variable at the same
time point. The EM model ﬁtting process is repeated for increasing
values for h and the transition matrix of the HMM is explored man-
ually each time for interesting features. We feel that this iterative
interactive approach is a good way to ensure interesting features
are identiﬁed:
Algorithm 2
Input: A set of pseudo time-series, P generated from cross
section data D and associated labels C
1. Remove the class labels C from P
2. Set h = max(C) (the number of classes) + 1
3. repeat
4. Train a HMM on the P with h hidden states using the EM
algorithm [14]
5. h = h + 1
6. until transition table in the parameterised HMM captures
disease features of interest (e.g. it features more than one
clear end state).
Output: HMM with new intermediate or end states.
We now describe the three clinical datasets, individually. Table 1
summarises all datasets.
2.2. Simulated data
To demonstrate the power of our method we ﬁrst illustrate the
performance on a number of simulated time-series generated from
an autoregressive HMM (ARHMM) [18,22–24] with two variables
for ease of visualisation (essentially it is a bivariate Gaussian).
200 time-series data are generated with four or ﬁve discrete states
in order to determine the trajectory of each time-series. The num-
ber of samples was chosen as it reﬂects the typical sample sizes
from the clinical data available. An ARHMM was used as it man-
ages to capture the relatively smooth transition from healthy to
disease states through autoregressive dependencies. This smooth
transition is typical in many medical data and in particular pro-
gressive diseases such as glaucoma. Of course there are some dis-
eases where this may not hold such as those where symptoms can
ﬂuctuate, appearing and disappearing over the course of the dis-
ease. The states in the ﬁrst simulated dataset represent a starting
healthy region and one diseased region with two intermediate
states whilst the second dataset involves one starting state, two
end states and two intermediate states. The observed variables
are Gaussian and conditioned upon the hidden state and the same
variable at the previous time point. We set the length of each mul-
tivariate time-series to be 30, as this reﬂects common longitudinal
studies in the biological and medical literature. The hidden
variable always starts in the healthy state and has a probability
distribution that determines the probability of change to the inter-
mediate and end states. One point from each time-series is thenTable 1
Summary table of the three datasets.
Dataset Number of
variables
Number of
cases
% Of healthy
controls
Visual ﬁeld 12 163 51.9
Breast cancer 10 565 62.7
Parkinson
disease
22 195 24.6sampled to form a cross-section dataset. This process is similar
to that used in [10] and the cross-sectional data is plotted in
Fig. 1 including some example time-series. The original transition
matrix of the models is shown in Tables 2 and 4. The sampled
cross-sectional data is used to generate the PTS.
2.3. Visual ﬁeld test and Heidelberg retina tomography data
The Visual Field (VF) test assesses the sensitivity of the retina to
light. It is typically measured by automated perimetry, a technique
in which the subject views a dim background as brighter spots of
light are shone onto the background at various locations in a reg-
ular grid pattern. The brightness at which the subject sees the
spots of light is related to the retinal sensitivity. There are many
diseases and conditions that affect the VF, the most common being
neurological disease and glaucoma. For this paper, the data are
aggregated into average values based upon their association with
one of six nerve ﬁbre bundles based upon the mappings in [21].
The other type of data that we explore are Heidelberg Retinal
Tomography (HRT) data [25] and involves generating images of
the retina in order to calculate certain measurements associated
with the three dimensional shape of the optic nerve head. These in-
clude neuro-retinal rim area, which are used for the experiments in
this paper. The measurements are calculated for six different seg-
ments: nasal (n), nasal inferior (ni) and superior (s), temporal (t),
temporal inferior (ti) and temporal superior (ts). For the experi-
ments in this paper, we combine the VF and HRT datasets to see
if trajectories that are identiﬁed capture the interaction between
the two data types as glaucoma progresses. The VF and HRT data
are taken from a study of approximately 160 people [26] and each
patient is classiﬁed into healthy or glaucomatous based upon the
VF data using a pre-deﬁned algorithm (AGIS) as used by clinicians
[27]. This may result in a bias towards the VF data for the building
of the pseudo time-series but as the relabelling algorithm involves
learning the states from scratch we do not envisage it biasing our
ﬁnal disease stages.
2.4. Breast cancer data
The Breast Cancer data (BC) are classiﬁed into 212 malignant
and 357 benign cases. Ten real-valued features are computed for
each cell nucleus: radius, texture, perimeter, area, smoothness,
compactness, concavity, concave points, symmetry, and fractal
dimension. The original dataset is described in more detail in
Wolberg and Mangasarian and is available on the UCI machine-
learning repository [28].
2.5. Parkinson’s disease data
Parkinson’s disease (PD) affects movement and motor-related
symptoms including speech. Vocal impairment can be the earliest
indicator for the onset of the PD. Therefore, a number of voice mea-
surements have drawn signiﬁcant attention for detecting and
tracking the progression of symptoms of PD [29]:
 The average vocal fundamental frequency (MDVP: Fo (Hz)).
 The maximum vocal fundamental frequency (MDVP: Fhi
(Hz)).
 The minimum vocal fundamental frequency (MDVP: Flo
(Hz)).
 Several measures of variation in fundamental frequency
(MDVP: Jitter (%), MDVP: Jitter (Abs), MDVP: RAP, MDVP:
PPQ, Jitter: DDP).
 Several measures of variation in amplitude (MDVP: Shim-
mer, MDVP: Shimmer (dB), Shimmer: APQ3, Shimmer:
APQ5, MDVP: APQ, Shimmer: DDA).
Fig. 1. Two simulated datasets generated using autoregressive HMMs with two variables to model disease processes. The plots show a single sampled point from each time-
series (dots) along with some of the original time-series (lines). One dataset has 1 healthy state, 1 disease state and 2 intermediate states (left); and the other has 1 healthy
state, 2 disease states and 2 intermediate states (right).
Table 3
Transition matrix learnt from PTS discovered from cross-sectional sample of
simulated time-series with four states.
Ht1/ht 1 2 3 4
1 0.8325 0.0612 0.0913 0.0150⁄
2 0.2765 0.5664 0.0000 0.1571
3 0.2131 0.0000 0.7291 0.0578
4 0.0000 0.0249⁄ 0.0769⁄ 0.8982
Table 4
Transition matrix for hand-coded simulated data with ﬁve states.
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voice status (NHR, HNR).
 Two nonlinear dynamical complexity measures (RPDE, D2).
 The signal fractal scaling exponent (DFA).
 Three nonlinear measures of fundamental frequency varia-
tion (spread1, spread2, PPE).
The PD dataset is composed 195 biomedical voice measure-
ments, 147 of which are from Parkinson’s disease patients and
48 from controls. The original dataset was obtained by McSharry
and Roberts and is available on the UCI machine-learning reposi-
tory [30].Ht1/ht 1 2 3 4 5
1 0.8000 0.0500 0.0500 0.0500 0.0500
2 0.0500 0.9000 0.0000 0.0500 0.0000
3 0.0500 0.0000 0.9000 0.0000 0.0500
4 0.0000 0.0000 0.0000 1.0000 0.0000
5 0.0000 0.0000 0.0000 0.0000 1.0000
Table 5
Transition matrix learnt from PTS discovered from cross-sectional sample of
simulated time-series with ﬁve states.
Ht1/ht 1 2 3 4 5
1 0.8915 0.0281 0.0455 0.0151 0.0198
2 0.0758 0.6863 0.0000 0.2379 0.0000
3 0.1191 0.0000 0.5768 0.0000 0.3041
4 0.0018⁄ 0.0157⁄ 0.0000 0.9514 0.0311⁄
5 0.0858 0.0000 0.0696⁄ 0.0039⁄ 0.84073. Experiments and results
3.1. Simulated results
The transition matrices generated from applying Algorithm 1 to
the two simulated datasets are shown in Tables 3 and 5, and can be
compared to the original matrices in Tables 2 and 4. It can be seen
that whilst the precise probabilities are not discovered, the general
characteristics of many of the states are found. For example, the
stable end states (state 4 in Table 2, and states 4 and 5 in
Table 4) are discovered. There are of course spurious dynamics
discovered. For example, states marked with an asterisk corre-
spond to zero probabilities in the original model. These spurious
correlations are small though we did ﬁnd that as we reduced the
sample size of the original data (to 50 or less) they become more
of an issue. They are likely to be because the HMM learnt has over-
ﬁtted to spurious relationships in the PTS through implicit correla-
tions. In summary, the main characteristics of the transitions are
preserved when the sample size is appropriately high. A small
number of spurious correlations between impossible transitions
were observed but these were always very low values. This gives
us conﬁdence in exploring the real-world clinical datasets with
similar sample sizes.Table 2
Transition matrix for hand-coded simulated data with four states.
Ht1/ht 1 2 3 4
1 0.8000 0.1000 0.1000 0.0000
2 0.0500 0.9000 0.0000 0.0500
3 0.0500 0.0000 0.9000 0.0500
4 0.0000 0.0000 0.0000 1.0000We now explore how the disease region identiﬁcation compares
to standard clustering techniques on real-world medical cross-
sectional data. For the real world data we do not know the true
underlying state transitions. We can, however, explore the discov-
ered transitions in the medical context. We document some
sample trajectories discovered using the temporal bootstrap on
each dataset when plotted on the ﬁrst two components after
applying multi-dimensional scaling. Points are separated as
healthy and diseased using red/dark grey and blue/light grey,
respectively. These ﬁgures are generated using multidimensional
scaling (calculated with Euclidean distances). This allows us to
visualise many more variables in two dimensions. We also
document ‘state diagrams’ to represent the transition probabilities
between the different states discovered. Associated with these
diagrams we report on the expected values and clustering values
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unlabelled pseudo time-series. We also show the mean values for
the data for healthy patients and diseased patients for comparison.
Note that Algorithm 2 involves increasing values for the hidden
state, h. Here, we only document results for models with the num-
ber of states that best compromise between ﬁnding new interest-
ing end and intermediate states and not ﬁnding trivial states that
are simply side-effects of the data. For the glaucoma data we found
four states best met this balance, for the breast cancer ﬁve states
met this criteria and for the Parkinson’s data three states. A larger
value for h led to the splitting of interpretable states into ones with
less clear signiﬁcance.Fig. 3. State transitions for glaucoma data. State 4 coincides with the starting
healthy state, 1 and 2 appear to represent relatively stable end states and 3 appears
a transitory state (a p > 0.15 is shown as a solid line and p > 0.05 as dashed).
Table 6
Transition matrix for discovered VF states.
Ht1/ht 1 2 3 4
1 0.9747 0.0253 0.0000 0.00003.2. Glaucoma results
3.2.1. The trajectories
Fig. 2 shows sample trajectories that are discovered when
building the pseudo time-series from healthy to disease regions.
It also highlights that there could be two distinct regions of
diseased state (in the top-right and bottom-right of the plots –
marked with two dashed ellipses). This is not obvious but our anal-
ysis aims to conﬁrm this through the relabelling scheme which we
use to identify the sequence transitions and their medical context.2 0.0509 0.7461 0.0897 0.1133
3 0.2749 0.0000 0.6827 0.0424
4 0.0000 0.0700 0.0990 0.83103.2.2. End-state analysis
Firstly we look at the glaucoma state transition diagram gener-
ated from the transition matrix of the learnt HMM in Fig. 3 (the ﬁg-
ure shows transitions with a p > 0.15 as solid lines and p > 0.05 as
dashed). The full transition matrix is given in Table 6 where ht rep-
resents the hidden state h at time t.
The table and diagram show that there appear to be three rela-
tively stable states: 1, 2 and 4. State 4 coincides with the starting
healthy state, 1 and 2 appear to represent relatively stable end
states and 3 appears a transitory state. We now explore these
states further by calculating the expected values of the variables
associated with each state (Fig. 5 left), the clustering values of
the variables discovered using k-means clustering (Fig. 5 right)
and compare to the mean values for normal and glaucomatous
data in Fig. 4. As expected State 4 in Fig. 5a shows a normal rim
width and VF sensitivity (similar values to the control in Fig. 5 with
high NFB sensitivity and low rim-associated variables), whereas
State 1 shows marked diffuse rim narrowing (high values for the
rim-associated variables), and moderate loss of retinal sensitivityFig. 2. Typical trajectories learnt from the combined VF and HRT data plotted using
multidimensional scaling with Euclidean distance. Normal VFs are marked in red
and glaucomatous in blue (left). (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)(low values for the NFB sensitivities) similar to the glaucomatous
in Fig. 3.
This is what would be expected, based on known anatomical
relationships. State 3 (an apparently transitory state) displays nar-
rowing of rim but little reduction of retinal sensitivity whilst State
2 (a relatively stable state) shows some narrowing of rim, but no
loss of retinal sensitivity. This characteristic of progressing in the
ﬁeld but not the in the optic disc (as displayed in the HRT rim data)
and vice versa is known to occur and it is interesting that these
have been identiﬁed by the algorithm as precursors to full disease
progression. More informative clusters are discovered using our
approach. What is more the pseudo-temporal models assist in
understanding this progression of Glaucoma.
3.3. Breast cancer results
3.3.1. The trajectories
Fig. 6 shows sample trajectories for the BC data. There is a clear
cluster of benign tumours in red and those classiﬁed as malignant
in blue. We now use the relabelling scheme to see if we can iden-
tify the state transitions from healthy/benign to malignant.
3.3.2. End-state analysis
The BC state transition diagram generated from the transition
matrix of the learnt HMM is illustrated in Fig. 7 (the ﬁgure shows
transitions with a p > 0.15 as solid lines and p > 0.05 as dashed).
The full transition matrix is given in Table 7. This table and dia-
gram show that there appear to be four relatively stable states:
2–5. State 3 appears to coincide with the starting benign state,
whilst 2 appears to represent a relatively stable malignant state,
and 1, 4 and 5 appear to be transitory states, with 5 being a key
stage in the progression to advanced malignant tumour. We now
explore these states further by comparing the mean data for the
pre-classiﬁed benign and malignant states (Fig. 8) with the ex-
pected values of the variables associated with each discovered
state as shown in Fig. 9 (left), and the clustering values for the
BC data using k-means clustering as shown in Fig. 9 (right).
Fig. 4. The mean data for the VF (left) and HRT (right) data as pre-classiﬁed using clinical analysis.
Fig. 5. The expected data for VF and HRT discovered using Algorithm 2 (left); the mean cluster proﬁles for VF and HRT discovered using k-means clustering (right).
Fig. 6. Typical trajectories learnt from the BC data. Benign are marked in red and
malignant in blue (left). (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
Fig. 7. The state transitions for the BC data. Where state 3 appears to coincide with
the starting benign state, whilst 2 appears to represent a relatively stable malignant
state, and 1, 4 and 5 appear to be transitory states, with 5 being a key stage in the
progression to advanced malignant tumour (a p > 0.15 is shown as a solid line and
p > 0.05 as dashed).
Table 7
Transition matrix for discovered BC states.
Ht1/ht 1 2 3 4 5
1 0.6963 0.0000 0.0403 0.0541 0.2093
2 0.0000 1.0000 0.0000 0.0000 0.0000
3 0.0959 0.0000 0.8929 0.0112 0.0000
4 0.0417 0.0377 0.1021 0.7764 0.0422
5 0.0000 0.1464 0.0000 0.0629 0.7907
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mours (generally low values for all metrics as is seen in the benign
cases in Fig. 8), whereas State 2 represents cases of malignant BC
(with generally high values as seen in the malignant cases in
Fig. 8). Interestingly, State 5 (which looks like an intermediate
stage in a trajectory that will ultimately be in a state characterised
as a malignant tumour) shows characteristics of a malignant tu-
mour but only in some variables such as high values for radius,
Fig. 8. The mean data values for the pre-classiﬁed benign and malignant cases.
Fig. 10. Typical trajectories learnt from the PD data. Healthy are marked in red and
Parkinsonism in blue. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
Fig. 11. The state transitions for the PD data. Where state 1 coincides with the
starting healthy state and 2 appear to represent a stable end state with 3 a
transitory state (a p > 0.15 is shown as a solid line and p > 0.05 as dashed).
Table 8
Transition matrix for discovered PD states.
Ht1/ht 1 2 3
1 0.8860 0.0000 0.1140
2 0.0000 1.0000 0.0000
3 0.0771 0.0482 0.8748
272 Y. Li et al. / Journal of Biomedical Informatics 46 (2013) 266–274perimeter and concave points whilst other variables such as fractal
complexity appear normal.
Here, the expected values from our approach are not really any
more informative than k-means. However, our approach still offers
the advantage of building transition models which help to under-
stand the progression of the disease.
3.4. Parkinson’s disease results
3.4.1. The trajectories
Fig. 10 shows a curved trajectory from healthy to Parkinsonism.
Notice the small cluster of healthy patients that appear to sit half-
way through this trajectory after many other patients have been
classiﬁed as sufferers (marked with a dashed circle). This could
be due to demonstrating a subset of symptoms and we now ex-
plore this by using the relabelling scheme.
3.4.2. End-state analysis
The PD state transition diagram generated from the transition
matrix of the learnt HMM is shown in Fig. 11 (the ﬁgure shows
transitions with a p > 0.15 as solid lines and p > 0.05 as dashed).
The full transition matrix is given in Table 8. This table and dia-
gram show that there appear to be two relatively stable states: 1
and 2. State 1 coincides with the starting healthy state and 2 ap-
pear to represent a stable end state with 3 a transitory state.
The expected values of the variables associated with each state
is shown in Fig. 13 (top), the clustering values using k-means
is shown in Fig. 13 (bottom) and the mean values for the pre-Fig. 9. The expected values of data for each state discovered from the relabelling sche
clustering (right).classiﬁed Parkinsonism patients and controls are shown in
Fig. 12. State 1 in Fig. 13 (top) shows people with a healthy proﬁle
very similar to the control proﬁle in Fig. 12. State 2 appears to
resemble people with PD, especially in the measurements of HNRme on the BC data (left); the mean cluster proﬁles for the BC data using k-means
Fig. 12. The mean PD data as pre-classiﬁed control and Parkinson’s disease.
Fig. 13. The mean cluster proﬁles using k-means (top). The expected data for each discovered state in the Parkinsonism data (bottom).
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sents Harmonics to Noise Ratio and is one of the most popular ap-
proaches to measuring voice function [9]. The three MDVP metrics
capture the average, maximum and minimum vocal fundamental
frequency. In addition, DFA is one of the parameters currently used
to distinguish healthy people and people with PD, the scaling expo-
nent of DFA is larger for PD than healthy people. It is positive to see
that the scale of this for State 2 is larger than the states 1 and 3. PEE
is a new measure of PD dysphonia, F0 is the natural pitch of
healthy voices. State 2 seems to be characterised by a much larger
vibrato and microtremor than State 1. Jitter is another feature of PD
and control measure values should be close to 0, as we see in the
State 1. State 3 appears to be a transition state somewhere be-
tween the control and PD stages where certain key features seem
to show characteristics of PD (such as RPDE and DFA) whilst others
resemble those of the controls. This state could account for the
cluster of apparently healthy individuals that look as if they arepart way along the trajectory in Fig. 10. The expected results using
our approach have more informative clusters than static clustering
the original cross-sectional data. This is likely to be due to the ex-
plicit modelling of the dynamics of the disease.4. Conclusions
There is considerable biomedical cross-sectional data being col-
lected but being able to model trajectories and the temporal aspect
of disease from these is problematic. In this paper, we have demon-
strated an extension of a method that we have previously pub-
lished for building pseudo time-series and tested it on a number
of diverse disease studies: glaucoma using visual ﬁeld test data,
breast cancer using tumour image data and Parkinson’s disease
using speech data. In this paper, we explore two issues: ﬁrstly,
how to build time-series models from cross-sectional data, and
274 Y. Li et al. / Journal of Biomedical Informatics 46 (2013) 266–274secondly how to automatically identify different disease states
along these trajectories, as well as the transitions between them.
We explore a comparison of this approach to standard clustering
techniques on the original cross-sectional data. We document
some promising results: for the glaucoma data we have been able
to identify stable states with abnormal VF sensitivity and marked
rim narrowing and transitory states with moderate narrowing of
rim, and subtle loss of retinal sensitivity in the central macula. This
ﬁts with current knowledge of the progression of glaucoma where
initial symptoms can appear in the rim but not the visual ﬁeld and
vice versa. In the cancer data we have identiﬁed stable states that
reﬂect the benign and malignant tumour states as well as an inter-
mediate state that is characterised by a subset of the symptoms of
malignant tumours. For the Parkinson’s disease data we discovered
a transitory state which has certain characteristics of Parkinsonism
despite being pre-classiﬁed as symptoms of controls. Our approach
of relabelling pseudo time-series allows us to explore the temporal
nature of how diseases such as those explored in this paper
progress.
Other similar studies explore the progression of disease through
latent variables but using longitudinal data. For example, studies
that model non-stationary time-series using state-space models
have been developed that will simultaneously ﬁt dynamic time-
series model parameters whilst identifying changes in the underly-
ing state [31,32]. However, none of these, attempt to exploit the
smoothness of disease progression to ﬁt trajectories through
cross-sectional data (which is much more abundant in clinical
applications) in order to build time-series models and understand
progression. This is what we present here. We intend to expand
this research to deal with multiple studies where we can combine
both cross-sectional and longitudinal datasets and to focus on the
junctions of the trajectories as key stages in the progression of
disease.
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